King for a Day? On What’s Wrong With Changing the World for the Better
By Roland Nadler,
Law and Biosciences Blog
| 01. 04. 2016
Untitled Document
Philosopher Russell Blackford argues that regulatory authorities should not allow “the tyranny of mere public opinion” to impede technological advances in genomics. I disagree strenuously. To explain why, let’s talk for a minute about … Mark Zuckerberg.
It was perhaps the last big Silicon Valley news story of 2015: Facebook’s CEO blew the headlines wide open when he and Dr. Priscilla Chan announced that they will dedicate 99% of their Facebook shares to their eponymous charitable LLC within their lifetimes. Widespread adulation was the order of the day.
You don’t have to be Gawker gadfly Sam Biddle to find some cause for concern, though. Two unelected, unaccountable magnates now wield a $45 billion policymaking LLC, unimpeded by the usual tax-law strictures for charitable organizations. They can and will remake swaths of the world as they see fit. What’s your recourse if you disagree with their definition of “better”? (Think you’ll never disagree? I’ve got some New Jersey charter schools to sell you.)
So, why rehearse the well-worn debate over philanthropy’s democratic legitimacy on a law and biosciences blog? Money isn’t the only way to change the world. Teams...
Related Articles
By staff, Japan Times | 12.04.2025
Japan plans to introduce a ban with penalties on implanting a genome-edited fertilized human egg into the womb of a human or another animal amid concerns over "designer babies."
A government expert panel broadly approved a proposal, including the ban...
By David Jensen, The California Stem Cell Report | 12.11.2025
California’s stem cell and gene therapy agency today approved spending $207 million more on training and education, sidestepping the possibility of using the cash to directly support revolutionary research that has been slashed and endangered by the Trump administration.
Directors...
By Tina Stevens, CounterPunch | 12.11.2025
Silicon Valley and other high tech billionaires are investing millions in start-ups dedicated to creating genetically engineered (GE) babies, according to a recent Wall Street Journal (WSJ) report. AI mogul Sam Altman, cryptocurrency entrepreneur Brian Armstrong, venture capitalist Peter...
By Jenny Lange, BioNews | 12.01.2025
A UK toddler with a rare genetic condition was the first person to receive a new gene therapy that appears to halt disease progression.
Oliver, now three years old, has Hunter syndrome, an inherited genetic disorder that leads to physical...